**Table 1. Categorical ranking scale for the clinical improvement of COVID-19**

|  |  |  |
| --- | --- | --- |
| **Patient status** | **Description** | **Category** |
| Non-infected | No clinical or virological signs of infection | 0 |
| Outpatient | No activity restrictions | 1 |
| Activity restrictions | 2 |
| Hospitalized | No oxygen therapy | 3 |
| mild | Oxygen therapy with a mask or nasal cannula | 4 |
| severe | Non-invasive ventilation or high-flow oxygen therapy | 5 |
| Intubation or mechanical ventilation | 6 |
| Mechanical ventilation + advanced organ support: vasopressors, renal replacement therapy, extracorporeal membrane oxygenation | 7 |
| Deceased | Fatal outcome | 8 |

**Table 2. The clinical status scale for a COVID-19 patient**

|  |  |  |
| --- | --- | --- |
| **Patient status** | **Description** | **Score** |
| No infection | No clinical manifestation and no laboratory confirmation of the COVID-19 infection | 0 |
| Outpatient | No clinical manifestations, COVID-19 confirmed by laboratory work-up | 1 |
| Clinical manifestations present, no limitations of daily activities | 2 |
| Clinical manifestations present, daily activities limited | 3 |
| Inpatient | Oxygen therapy not required | 4 |
| Oxygen therapy required (mask or nasal cannula) | 5 |
| Inpatient, severe course | Non-invasive ventilation or high flow oxygen therapy | 6 |
| Intubation and MV, pO2/FiO2 ≥ 150 or SpO2/FiO2 ≥ 200 | 7 |
| MV, pO2/FiO2 < 150 (SpO2/FiO2 < 200) or the use of vasopressor agents | 8 |
| MV, pO2/FiO2 < 150 + treatment of organ failure (vasopressor agents, extracorporeal membrane oxygenation, renal replacement therapy) | 9 |
| Deceased | Death outcome | 10 |

MV, mechanical ventilation

**Table 3. Baseline demographic, anthropometric, and clinical characteristics of the study patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Molnupiravir (n = 120)** | **Standard therapy (n = 120)** | **All patients (n = 240)** |
| Age, years (range) | 42.4 (18–77) | 44.7 (18–74) | 43.5 (18–77) |
| Males, n (%) | 50 (41.6) | 42 (35.0) | 92 (38.3) |
| BMI, kg/m2 (range) | 27.4 (18–51) | 28.0 (18–35) | 27.7 (18–51) |
| Concomitant diseases/conditions\*, n (%) | 85 (70.8) | 84 (70.0) | 169 (70.4) |
| Asthma, n (%) | 5 (4.5) | 3 (2.5) | 8 (3.5) |
| Chronic bronchitis, n (%) | 5 (4.5) | 2 (1.7) | 7 (3.0) |
| Hypertension, n (%) | 41 (36.9) | 39 (32.8) | 80 (34.8) |
| Coronary heart disease, n (%) | 4 (3.6) | 1 (0.8) | 5 (2.7) |
| Obesity, n (%) | 36 (32.4) | 42 (35.3) | 78 (33.9) |
| Chronic gastritis, n (%) | 3 (2.7) | 2 (1.7) | 5 (2.8) |
| Chronic pyelonephritis, n (%) | 3 (2.7) | 4 (3.3) | 7 (3.0) |
| Menopause, n (%) | 3 (2.7) | 6 (5.0) | 9 (3.9) |

\* In addition to those indicated in the table, the following comorbidities were identified with a frequency of ≤3 in the total study patient population: varicose vein disease (1), hypercholesterolemia (1), duodenal ulcer (1), iron deficiency anemia (2), ischemic cardiomyopathy (1), cardiomyopathy (1), cataract (1), diverticulitis (1), uterine fibroids (2), myopia (1), impaired glucose tolerance (1), osteochondrosis (1), degenerative spinal disease (1), gout (1), allergic rhinitis (1), seasonal allergic rhinitis (1), type 1 diabetes (1), retinal vascular disease (1), coronary artery disease, angina (2), post-cholecystectomy syndrome (1), chronic obstructive pulmonary disease (1), chronic sinusitis (1), chronic calculous cholecystitis (2), essential hypertension (3)

**Table 4. Proportion of the patients (%) with a change in their clinical status on the categorical ranking scale for clinical improvement (ITT analysis)**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Achieved category 0** | **Achieved category 1** |
| Mol |  |  |
| day 0\* S | – | – |
| P value |  |  |
| Mol | 19.17 | 22.50 |
| day 6–7 S | 6.67 | 11.67 |
| P value | 0.0039 | 0.0258 |
| Mol | 57.50 | 60.83 |
| day 11–12\*\* C | 43.33 | 44.17 |
| P value | 0.0282 | 0.0097 |
| Mol | 80.83 | 82.50 |
| day 14–15 S | 75.83 | 75.83 |
| P value | 0.3472 | 0.2035 |

Mol – Molnupiravir, S – standard therapy

\* No data available at day 0. Initiation of therapy. Evaluation point of clinical status

\*\* Ending of therapy